impairment of capital

impairment of capital的基本解释

-

亏绌

-

资本减损

与impairment of capital相关的网络例句 [注：此内容来源于网络，仅供参考]

Of Health stressed that the company in November last year from the date of the Group of Fortis shares with a total investment cost of 23,874,000,000 yuan, the impairment provision, the capital of the company to maintain Adequate, stable financial base, will remain solvent in more than 300 percent, fully meet the various needs of the development of the business units.

卫生强调说，在去年11月公司从富通集团股份的日期，总投资238.74亿元成本，减值准备，公司的资本，以维持充足的，稳定的金融基地，将继续溶剂超过3倍，完全符合有关业务单位的发展的各种需要。

In response, China last night safely in its announcement made it clear that regardless of whether the three in the Quarterly Bulletin of the Fortis shares provision for impairment of investment capital and solvency is still very adequate, still robust financial, insurance, banking, Trust, securities and other main business is healthy growth, good customer rights and interests will be adequately protected.

对此，中国昨晚在其安全公告明确表示，无论这三个在富通股票的投资资本和偿付能力减值拨备季报仍然十分充足，仍然强劲的金融，保险，银行，信托，证券和其他主要业务是健康成长，良好的客户的权利和利益将得到充分的保障。

Shareholders who didn't anticipate the newspaper's gradual obsolescence and bought shares of The New York Times around $50 per share back in 2004 have probably suffered a permanent impairment of capital.

那些没有预料到报业渐逐没落，在纽约时报（纽约证券交易所代码：NYT）约每股$50时买了股票的股东，早在2004年就可能受到永久资产损失。

Factors that could affect results include the ability to market and sell products; changes in relationships with strategic partners and reliance on strategic partners for the performance of critical activities under collaborative arrangements; failure of distributors or other customers to meet purchase forecasts or minimum purchase requirements for our products; impact of competitors, competing products and technology changes; ability to develop, commercialize and market new products; market acceptance of oral fluid testing or other new products or technology; changes in market acceptance based on product performance; continued bulk purchases by customers, including governmental agencies, and the ability to fully deploy those purchases in a timely manner; ability to fund research and development and other products and operations; ability to obtain and maintain new or existing product distribution channels; reliance on sole supply sources for critical product components; availability of related products produced by third parties; ability to obtain, and timing and cost of obtaining, necessary regulatory approval for new products or new indications or applications for existing products; ability to comply with applicable regulatory requirements; history of losses and ability to achieve sustained profitability; volatility of our stock price; uncertainty relating to patent protection and potential patent infringement claims; uncertainty and costs of litigation relating to patents and other intellectual property; availability of licenses to patents or other technology; ability to enter into international manufacturing agreements; obstacles to international marketing and manufacturing of products; ability to sell products internationally; loss or impairment of sources of capital; ability to meet financial covenants in agreements with financial institutions; ability to retain qualified personnel; exposure to product liability, patent infringement, and other types of litigation; changes in international, federal or state laws and regulations; customer consolidations and inventory practices; equipment failures and ability to obtain needed raw materials and components; the impact of terrorist attacks and civil unrest; ability to complete consolidation or restructuring activities; ability to identify, complete and realize the full benefits of potential acquisitions; and general political, business and economic conditions.

可能影响结果的因素包括营销以及出售产品的能力；与战略合作伙伴关系的变化以及根据合作协议对战略合作伙伴执行关键活动的依赖；经销商或者其他顾客未达到我方产品的采购预测或者最低采购要求；竞争对手、竞争产品以及技术变化的影响；新产品开发、商业化以及营销的能力；市场对唾液检测、其他新产品或者技术的接收程度、基于产品效果所造成的市场接收的变化；顾客、包括政府机构的持续大宗采购以及按时完成采购的能力；资助研究、开发以及其他产品和活动的能力；获得并维持新的或者现有的产品经销渠道的能力；关键产品部件对单一供应源的依赖；第三方生产的相关产品的供应情况；新产品或者现有产品的新疗效获得必要的管制批准的能力、时间以及费用；遵守适用的管制要求的能力；亏损的历史以及实现可持续盈利的能力；股票价格的波动；与专利保护和潜在的专利侵权诉讼有关的不确定性；与专利以及其他知识产权有关的不确定性以及诉讼费用；专利以及其他技术授权的提供情况；签订国际性制造协议的能力；产品进行国际营销以及制造的障碍；国际性销售产品的能力；资本来源的损失或者减少；履行与财务机构之间协议的能力；获得合格人员的能力；产品责任、专利侵权以及其他诉讼的风险；国际、联邦或者州的法律、法规的变化；顾客合并以及存货实践；设备故障以及获得所需原材料和部件的能力；恐怖主义袭击以及内乱的影响；完成合并或者重组活动的能力；识别、完成以及实现潜在收购的全部利益的能力；一般性政治、商业、经济形势等。

与impairment of capital相关的网络解释 [注：此内容来源于网络，仅供参考]

impairment of capital：资本减损

1948 illiquidity 非流动性 | 1949 impairment of capital 资本减损 | 1950 impairment of value 价值减损

impairment of capital：资本减损 impairment of capital 资本减损

1948 1 illiquidity 非流动性 illiquidity 非流动性 | 1949 1 impairment of capital 资本减损 impairment of capital 资本减损 | 1950 1 impairment of value 价值减损 impairment of value 价值减损

impairment of capital：资本亏损

资本亏绌 capital deficiency | 资本亏损 impairment of capital | 资本弱化 thin capitalization

Impairment of capital account：亏绌帐户

Immovables real estate 不动产 | Impairment of capital account 亏绌帐户 | Impersonal account 非人名帐户

Impairment of capital account：专绌帐户

immovable property,real property 不動產 | impairment of capital account 專絀帳戶 | impersonal account 非人名帳戶